Skip to content

Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction

Hypoxemia, Dyspnea, and Exercise Tolerance in Patients With Pulmonary Arteriovenous Malformations , With and Without Airflow Obstruction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02458703
Acronym
ExercisePAVM2
Enrollment
60
Registered
2015-06-01
Start date
2015-05-31
Completion date
2018-05-31
Last updated
2015-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, COPD, Hereditary Hemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformations

Keywords

workload, oxygen level, oxygen consumption, breathing reserve, ventilatory efficiency

Brief summary

Pulmonary arteriovenous malformations (PAVMs) are a rare vascular condition affecting the lungs. PAVMs lead to low blood oxygen levels, yet are very well tolerated by patients. This study will examine the exercise capacity of PAVM patients using formal cardiopulmonary exercise tests performed on a stationary bicycle, and whether this is affected by the presence of concurrent airflow obstruction, such as due to asthma.

Detailed description

It is well known that the lung is the site at which oxygen enters the blood stream, diffusing from the alveolar air sacs into the pulmonary capillaries. This newly oxygenated blood is carried to the heart in the pulmonary veins, then passes into the systemic circulation to provide oxygen to the tissues. Patients with pulmonary arteriovenous malformations (PAVMs) have abnormal vascular connections between pulmonary arteries and pulmonary veins in the lung. Blood flowing through PAVMs therefore bypasses the oxygenation sites in the pulmonary capillaries. Low blood oxygen levels (hypoxemia) is frequent in PAVM patients but breathlessness (dyspnea) is not. The investigators have shown that dyspnea was not a common presenting complaint in a large UK series, and that there is little correlation between severity of dyspnea in PAVM patients, and blood oxygen levels. In this study the investigators will address the question Do PAVM patients have lower exercise tolerance if they have concurrent airflow obstruction? The primary outcome measure will be the total body oxygen consumption in mls/min/kg, at peak exercise (the V\[dot\]O2 peak (also known as VO2 max)). The investigators will address this by first performing standardised cardiopulmonary exercise testing, as used in the clinic and our previous study (11/H0803/9), on age and sex matched patients with PAVMs. 30 will be recruited with airflow obstruction, and 30 without airflow obstruction. Physiological parameters will be compared, to test the null hypothesis that the impact of exercise on PAVM patients' cardiopulmonary systems does not differ according to the presence or absence of airflow obstruction. Cellular and molecular methods will be used to dissect mechanistic pathways.

Interventions

OTHERCardiopulmonary exercise test

Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis.

Sponsors

Imperial College London
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Ability to provide informed consent * Pulmonary AVMs no airflow obstruction: Pulmonary AVMs confirmed by CT scan and no evidence or history of airflow obstruction on clinical grounds, or by spirometric evaluations. * Pulmonary AVMs with airflow obstruction: Pulmonary AVMs confirmed by CT scan and evidence or history of airflow obstruction on clinical grounds, and/or by spirometric evaluations (such as FEV1/VC ratio \<80%).

Exclusion criteria

* Inability to provide informed consent * Any known cardiovascular abnormality including a history of syncope (faintness, dizziness, lightheadedness or loss of consciousness due to an abnormality of the cardiovascular system). * Current respiratory tract infection (eg a cold). * Pregnancy. * Claustrophobia or needle phobia

Design outcomes

Primary

MeasureTime frameDescription
Total body oxygen consumption in mls/min/kg, at peak exercise (VO2 max).Same day (within 1 hour), at end of exercise studyOf the many measurements and derived indices that can be measured during cardiopulmonary exercise testing, the peak consumption of oxygen (VO2 max) is perhaps the best indicator of integrated cardiorespiratory capacity. The principle research question will therefore test the null hypothesis that The VO2 max does not differ between PAVM patients with and without airflow obstruction.

Secondary

MeasureTime frameDescription
Breathing reserveSame day (within 1 hour), at end of exercise studyWe will also test in univariate and multiple regression analyses whether breathing reserve differs between PAVM patients with and without airflow obstruction.
Ventilatory efficiencySame day (within 1 hour), at end of exercise studyWe will also test in univariate and multiple regression analyses whether ventilatory efficiency differs between PAVM patients with and without airflow obstruction.

Contacts

Primary ContactClaire L Shovlin, PhD FRCP
c.shovlin@imperial.ac.uk44 208 282 2352
Backup ContactLuke Howard, DPhil FRCP
l.howard@imperial.ac.uk44 208 282 2352

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026